CNS Pharmaceuticals (CNSP) Accounts Payables (2018 - 2025)
CNS Pharmaceuticals' (CNSP) quarterly Accounts Payables came in at $3.8 million in Q4 2025, up 71.61% YoY from $2.2 million in Q4 2024, and up 95.63% on a QoQ basis from $1.9 million in Q3 2025.
CNS Pharmaceuticals (CNSP) Accounts Payables (2018 - 2025) Analysis & Trends
CNS Pharmaceuticals (CNSP) has 8 years of Accounts Payables data on file, last reported at $3.8 million in Q4 2025.
- Quarterly Accounts Payables rose 71.61% year-over-year to $3.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.8 million (up 71.61% YoY) and the FY2025 annual result came in at $3.8 million, up 71.61% from the prior year.
- Accounts Payables climbed to $3.8 million in Q4 2025, from $1.9 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $6.6 million in Q2 2024 to a low of $826061.0 in Q1 2022.
- A 5-year average of $2.9 million and a median of $2.4 million in 2024 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2021 — Accounts Payables surged 648.82% — and 2025, when it sank 81.01%.
- Tracing CNSP's Accounts Payables over 5 years: stood at $2.0 million in 2021, then soared by 127.63% to $4.5 million in 2022, then grew by 29.31% to $5.8 million in 2023, then slumped by 62.31% to $2.2 million in 2024, then jumped by 71.61% to $3.8 million in 2025.
- The last three Accounts Payables figures came in at $3.8 million (Q4 2025), $1.9 million (Q3 2025), and $1.3 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | CNS Pharmaceuticals | 2.65 Mn | -4.55 Mn | - | 3.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.77 Mn |
| Sep 30, 2025 | 1.93 Mn |
| Jun 30, 2025 | 1.26 Mn |
| Mar 31, 2025 | 2.57 Mn |
| Dec 31, 2024 | 2.20 Mn |
| Sep 30, 2024 | 4.03 Mn |
| Jun 30, 2024 | 6.64 Mn |
| Mar 31, 2024 | 5.88 Mn |
| Dec 31, 2023 | 5.83 Mn |
| Sep 30, 2023 | 4.03 Mn |
| Jun 30, 2023 | 3.57 Mn |
| Mar 31, 2023 | 2.78 Mn |
| Dec 31, 2022 | 4.51 Mn |
| Sep 30, 2022 | 826,061.00 |
| Jun 30, 2022 | 1.32 Mn |
| Mar 31, 2022 | 826,061.00 |
| Dec 31, 2021 | 1.98 Mn |
| Sep 30, 2021 | 1.46 Mn |
| Jun 30, 2021 | 892,492.00 |
| Mar 31, 2021 | 1.06 Mn |